Moderna Inc

NASDAQ:MRNA   3:59:59 PM EDT
430.17
-24.43 (-5.37%)
: $429.41 -0.76 (-0.18%)
Products

Moderna Completes Submission Of Biologics License Application To The U.S. FDA For Its Covid-19 Vaccine

Published: 08/25/2021 13:49 GMT
Moderna Inc (MRNA) - Moderna Completes Submission of Biologics License Application to the U.S. Food and Drug Administration for Its Covid-19 Vaccine.
Moderna Inc - Efficacy Remains Durable Through Six Months After Second Dose.
Moderna Inc - Final Blinded Analysis of Phase 3 Cove Study of Moderna Covid-19 Vaccine Shows 93% Efficacy.
Moderna Inc - As Part of Completed Bla Submission, Moderna Has Requested Priority Review Designation.